Diabetes Therapeutics Market Report 2026

Diabetes Therapeutics Market Overview

• Diabetes Therapeutics market size has reached to $170.06 billion in 2025 • Expected to grow to $278.96 billion in 2030 at a compound annual growth rate (CAGR) of 10.3% • Growth Driver: Increasing Prevalence Of Obesity Fueling Growth Of The Market Due To Increasing Consumption Of High-Calorie Diets • Market Trend: Advancing Personalized Diabetes Care Through Digital Cognitive Behavioral Therapy • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Diabetes Therapeutics Market?

Diabetes therapeutics refers to the range of medical treatments and interventions used to manage and control diabetes, a condition characterized by high blood sugar levels due to problems with insulin production or use. These therapies include medications such as insulin (essential for type 1 diabetes and sometimes used in type 2), oral drugs such as metformin, and newer agents such as GLP-1 receptor agonists and SGLT2 inhibitors, which help lower blood glucose through various mechanisms. The main types of drugs in diabetes therapeutics are oral anti-diabetic drugs, insulin, non-insulin injectable drugs, and combination drugs. Oral anti-diabetic drugs are medicines taken by mouth to help lower blood sugar in people with diabetes. The multiple types involved are diabetes 1 and diabetes 2. The various routes of administration include oral, subcutaneous, and intravenous, which are distributed through various distribution channels such as online pharmacies, hospital pharmacies, and retail pharmacies, and cater to several applications such as prevention and treatment or care.

What Is The Diabetes Therapeutics Market Growth Forecast?

The diabetes therapeutics market size is expected to see rapid growth in the next few years. It will grow to $278.96 billion in 2030 at a compound annual growth rate (CAGR) of 10.3%. The growth in the forecast period can be attributed to development of novel insulin analogs, expansion of combination therapies, adoption of digital diabetes management tools, increasing healthcare infrastructure for diabetes care, integration of telemedicine and remote monitoring. Major trends in the forecast period include rising prevalence of diabetes globally, increasing adoption of glp-1 receptor agonists and sglt-2 inhibitors, expansion of online and retail pharmacies, growing focus on personalized diabetes management, enhanced awareness of preventive care and early diagnosis.

Global Diabetes Therapeutics Market Segmentation

1) By Drug: Oral Anti-Diabetic Drugs, Insulin, Non-Insulin Injectable Drug, Combination Drug 2) By Type: Diabetes 1, Diabetes 2 3) By Route Of Administration: Oral, Subcutaneous, Intravenous 4) By Distribution Channel: Online Pharmacies, Hospital Pharmacies, Retail Pharmacies 5) By Application: Preventive, Treatment Or Care Subsegments: 1) By Oral Anti-Diabetic Drugs: Biguanides, Sulfonylureas, DPP-4 Inhibitors, SGLT-2 Inhibitors, Thiazolidinediones, Meglitinides, Alpha-Glucosidase Inhibitors 2) By Insulin: Rapid-Acting Insulin, Short-Acting Insulin, Intermediate-Acting Insulin, Long-Acting Insulin, Premixed Insulin 3) By Non-Insulin Injectable Drug: GLP-1 Receptor Agonists, Amylin Analogs 4) By Combination Drug: Oral Combination Therapies, Oral and Injectable Combination Therapies

What Is The Driver Of The Diabetes Therapeutics Market?

The increasing prevalence of obesity is expected to propel the growth of the diabetes therapeutics market going forward. Obesity refers to excessive fat accumulation that presents a health risk and is a major risk factor for type 2 diabetes. The rising prevalence of obesity is due to increasing consumption of high-calorie diets, with more people eating processed and fast foods high in sugar and fat while engaging in less physical activity, leading to excessive weight gain. Diabetes therapeutics help manage obesity by improving blood sugar control and supporting weight loss through medications such as GLP-1 receptor agonists, which reduce appetite and slow digestion, enhancing overall metabolic health in obese individuals. For instance, in May 2024, according to a report published by the Office for Health Improvement and Disparities, a UK-based government department, in 2022 to 2023, approximately 64% of adults aged 18 and over were classified as overweight or living with obesity, showing a increase from the previous year's figure of 63.8%. Therefore, the increasing prevalence of obesity is driving the growth of the diabetes therapeutics industry.

Key Players In The Global Diabetes Therapeutics Market

Major companies operating in the diabetes therapeutics market are Pfizer Inc., Merck & Co Inc., Novartis AG, Sanofi S.A., AstraZeneca PLC, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Novo Nordisk A/S, Boehringer Ingelheim International GmbH, Biocon Biologics Limited, MannKind Corporation, Lexicon Pharmaceuticals Inc., Adocia S.A., Oramed Pharmaceuticals Inc.

Global Diabetes Therapeutics Market Trends and Insights

Major companies operating in the diabetes therapeutics market are focusing on developing innovative solutions, such as cognitive behavioral therapy (CBT), to enhance personalized diabetes management and improve glycemic control in patients with type 2 diabetes. Cognitive behavioral therapy (CBT) refers to a structured, evidence-based psychological treatment that helps individuals identify and change unhelpful thought patterns and behaviors. For instance, in October 2023, Better Therapeutics Inc., a US-based digital therapeutics company, launched AspyreRx, a digital diabetes therapeutic app. AspyreRx, which received FDA authorization for treating type 2 diabetes, provides tailored cognitive behavioral therapy (CBT) to patients aged 18 and older to support behavioral changes that improve diabetes management. Formerly known as BT-001, AspyreRx demonstrated statistically and clinically significant, durable reductions in A1c compared to standard care, along with improvements in blood pressure, weight, mood, and quality of life in a randomized controlled trial.

What Are Latest Mergers And Acquisitions In The Diabetes Therapeutics Market?

In June 2023, Eli Lilly and Company, a US-based pharmaceutical company, acquired Sigilon Therapeutics Inc. for $0.034 billion. With this acquisition, Eli Lilly aims to strengthen its position in diabetes care by advancing innovative cell therapies for type 1 diabetes, specifically by further developing Sigilon’s SIG-002 program, which seeks to restore insulin production through encapsulated islet cell replacement, potentially offering a functional cure and reducing the daily disease management burden for patients. Sigilon Therapeutics Inc. is a US-based biotechnology company that specializes in diabetic therapeutics.

Regional Insights

North America was the largest region in the diabetes therapeutics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Diabetes Therapeutics Market?

The diabetes therapeutics market consists of revenues earned by entities by providing services such as blood sugar monitoring, medication management, insulin therapy support, and lifestyle counseling. The market value includes the value of related goods sold by the service provider or included within the service offering. The diabetes therapeutics market also includes sales of insulin, oral hypoglycemic agents, GLP-1 receptor agonists, SGLT2 inhibitors, and DPP-4 inhibitors. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Diabetes Therapeutics Market Report 2026?

The diabetes therapeutics market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the diabetes therapeutics industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.